Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report
…, E Wieland, JB Woillard, MJ Barten… - Therapeutic drug …, 2019 - journals.lww.com
Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …
Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
T van Gelder, J Klupp, MJ Barten… - Therapeutic drug …, 2001 - journals.lww.com
Mycophenolate mofetil (MMF) is almost completely absorbed from the gut and is rapidly de-esterified
into its active drug, mycophenolic acid (MPA). The main metabolite is …
into its active drug, mycophenolic acid (MPA). The main metabolite is …
Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology
…, JB Woillard, TC Zwart, MJ Barten… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
Therapeutic drug monitoring of everolimus: a consensus report
…, M Brunet, K Budde, MJ Barten… - Therapeutic drug …, 2016 - journals.lww.com
In 2014, the Immunosuppressive Drugs Scientific Committee of the International Association
of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international …
of Therapeutic Drug Monitoring and Clinical Toxicology called a meeting of international …
[HTML][HTML] COVID-19 among heart transplant recipients in Germany: a multicenter survey
…, A Rieth, M Berchtold-Herz, MJ Barten… - Clinical Research in …, 2020 - Springer
Aims Heart transplantation may represent a particular risk factor for severe coronavirus
infectious disease 2019 (COVID-19) due to chronic immunosuppression and frequent …
infectious disease 2019 (COVID-19) due to chronic immunosuppression and frequent …
Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation
…, U Christians, M López-Hoyos, MJ Barten… - Therapeutic drug …, 2016 - journals.lww.com
With current treatment regimens, a relatively high proportion of transplant recipients experience
underimmunosuppression or overimmunosuppression. Recently, several promising …
underimmunosuppression or overimmunosuppression. Recently, several promising …
[HTML][HTML] Current trends in implantable left ventricular assist devices
J Garbade, HB Bittner, MJ Barten… - Cardiology research and …, 2011 - hindawi.com
The shortage of appropriate donor organs and the expanding pool of patients waiting for
heart transplantation have led to growing interest in alternative strategies, particularly in …
heart transplantation have led to growing interest in alternative strategies, particularly in …
The clinical impact of donor-specific antibodies in heart transplantation
MJ Barten, U Schulz, A Beiras-Fernandez… - Transplantation …, 2018 - Elsevier
Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection
(AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac …
(AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac …
Outcome of patients suffering from acute type B aortic dissection: a retrospective single-centre analysis of 135 consecutive patients
…, M Jenniches, MA Borger, MJ Barten… - European journal of …, 2010 - academic.oup.com
Objectives: Acute uncomplicated Stanford type B aortic dissection (TBAD) is optimally
managed with medical treatment. However, surgery and thoracic endovascular aortic repair (…
managed with medical treatment. However, surgery and thoracic endovascular aortic repair (…
Bridging INTERMACS 1 patients from VA-ECMO to LVAD via Impella 5.0: de-escalate and ambulate
…, E Lubos, H Grahn, M Rybczinski, MJ Barten… - Journal of Critical …, 2020 - Elsevier
Purpose Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) stabilizes patients
in refractory cardiogenic shock. However, ECMO-related complications strongly affect the …
in refractory cardiogenic shock. However, ECMO-related complications strongly affect the …